Search Results
Your search for 3 matches 15052 pages
Showing 10851 - 10900ASCO 2016: Significant Cost Differences Found Among Breast Cancer Chemotherapy Regimens
Costs associated with different breast cancer chemotherapy regimens can vary significantly, regardless of effectiveness, according to new research from The University of Texas MD Anderson Cancer Center. Understanding cost differences should help guide informed discussions between patients and...
First-Line Fludarabine, Cyclophosphamide, and Rituximab vs Bendamustine/Rituximab in Advanced CLL
In a European phase III noninferiority trial reported in The Lancet Oncology, Eichhorst et al found that progression-free survival was better with standard first-line fludarabine/cyclophosphamide/rituximab vs bendamustine/rituximab in fit patients with advanced chronic lymphocytic leukemia (CLL)...
ASCO 2016: Local Consolidative Therapy Improves Progression-Free Survival in Patients With Oligometastatic NSCLC vs Standard Chemotherapy
Lung cancer patients with oligometastases, defined as three or fewer sites of metastasis, may benefit from aggressive local therapy, surgery, or radiation, after standard chemotherapy, according to research led by The University of Texas MD Anderson Cancer Center. If validated in larger studies,...
Study Finds Apparent Benefit of Adding Fosbretabulin to Bevacizumab in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma
Adding the vascular-disrupting agent fosbretabulin to bevacizumab (Avastin) improved outcomes in patients with recurrent ovarian, tubal, or peritoneal carcinoma, according to a randomized phase II NRG Oncology/Gynecologic Oncology Group study reported in the Journal of Clinical Oncology by Monk et...
ASCO 2016: Vast Differences Globally in Cancer Drug Retail Prices
A pilot study revealed large differences in median retail prices for 23 cancer drugs in 7 different countries, with the highest retail prices identified in the United States and the lowest, in India and South Africa. Notably, after the monthly drug price is expressed as a percentage of domestic...
ASCO 2016: Many Younger Cancer Patients Receive Aggressive End-of-Life Care Despite ASCO’s Choosing Wisely Campaign
An analysis of health claims data from 2007–2014 on more than 28,000 patients under the age of 65 found that a large proportion of patients with advanced solid tumors received at least one form of aggressive care within the last 30 days of life. The study was presented by Chen et al at...
ASCO 2016: Study Finds Use of Mobile Web App Associated With Improved Outcomes in Lung Cancer
A Web-mediated follow-up application (app; Moovcare™) improved advanced lung cancer survival, according to a French multicenter randomized phase III study. Researchers analyzed the association and evolution of self-reported clinical symptoms over time. The median overall survival of patients...
ASCO 2016: Novel Antibody Significantly Improves Survival in Patients With Advanced Gastric Cancer
Findings from the European phase II FAST study showed that the novel, first-in-class antibody IMAB362 can significantly extend median survival when added to standard chemotherapy (13.2 vs 8.4 months) for patients with advanced gastric cancer. This therapy targets a protein called claudin-18 splice...
ASCO 2016: Tandem Autologous Stem-Cell Transplant Improves Outcomes for Children With High-Risk Neuroblastoma
Historically, less than 50% of children with high-risk neuroblastoma live 5 or more years after diagnosis. A National Cancer Institute (NCI)-funded phase III trial performed by the Children’s Oncology Group found that adding a second autologous stem-cell transplant to standard therapy...
ASCO 2016: Temozolomide Chemotherapy Plus Short-Course Radiotherapy Improves Survival in Elderly Patients With Glioblastoma
A Canadian-led randomized phase III trial found that adding temozolomide chemotherapy during short-course radiation therapy, followed by monthly maintenance doses of temozolomide, significantly improved survival of elderly patients with glioblastoma, reducing the risk of death by 33%. These data...
ASCO 2016: Rucaparib Shows Clinical Benefit in BRCA-Mutated Pancreatic Cancer
The targeted PARP inhibitor rucaparib, which has demonstrated robust clinical activity in patients with ovarian cancer who have a BRCA mutation, also showed promise in previously treated patients with pancreatic cancer who have the mutation, according to results from a phase II clinical study...
ASCO 2016: Precision Medicine Approach May Expand Therapeutic Options for Patients
Researchers reported encouraging early results from a phase II trial that matches patients with molecular abnormalities in the tumor to corresponding targeted treatments. Twenty-nine of 129 patients with 12 different types of advanced cancers responded to drugs outside of U.S. Food and Drug...
5-Year Results of DASISION Trial of Dasatinib vs Imatinib in CML
As reported in the Journal of Clinical Oncology by Cortes et al, the final 5-year results of the DASISION trial support the safety and efficacy of dasatinib (Sprycel) as first-line treatment in patients with chronic myeloid leukemia (CML) in chronic phase. Initial results in the trial led to...
ASCO Guideline on Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer
As reported by Hope S. Rugo, MD, of the University of California San Francisco Comprehensive Cancer Center, and colleagues in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline on endocrine therapy for hormone receptor–positive metastatic breast cancer. The...
International Prognostic Index for Patients With Chronic Lymphocytic Leukemia
The International Chronic Lymphocytic Leukemia–International Prognostic Index (CLL-IPI) working group has developed an IPI for patients with chronic lymphocytic leukemia based on a meta-analysis of individual patient data, as reported in The Lancet Oncology. Study Details The meta-analysis...
Women With New-Onset Atrial Fibrillation May Be at Increased Risk for Malignant Cancer
Among nearly 35,000 initially healthy women who were followed for about 20 years, those with new-onset atrial fibrillation had an increased risk of cancer, according to a study published by Conen et al in JAMA Cardiology. Atrial fibrillation, the most common cardiac arrhythmia, is associated with...
QOPI-Certified Practices Eligible to Receive Discount on Medical Malpractice Rates
ASCO and its wholly owned subsidiary, Quality Oncology Practice Initiative (QOPI®) Certification Program, LLC (QCP), announced May 25 that The Doctors Company, the nation's largest physician-owned medical malpractice insurer, will recognize QOPI® Certification in its rate structure....
New ASCO Cervical Cancer Guidelines Address Global Resource Disparities
On May 25, ASCO issued its first clinical practice guideline on invasive cervical cancer. This resource-stratified guideline is the first of its kind from ASCO, offering treatment recommendations tailored to resource availability. Access to cervical cancer care varies between regions of the...
External Validation of a Prediction Tool for Chemotherapy Toxicity in Older Patients With Cancer
Hurria et al validated a prediction tool for chemotherapy toxicity in cancer patients aged ≥ 65 years in an external cohort, according to a report in the Journal of Clinical Oncology. The predictive model had been developed in a prior study in 500 patients. Study Details The study...
Leisure-Time Physical Activity Reduces Risk of Multiple Cancer Types
In a study reported in JAMA Internal Medicine, Moore et al found that greater leisure-time physical activity was associated with a reduced risk for many types of cancer. Study Details The study used pooled data on 1.44 million adults from 12 prospective U.S. and European cohorts with...
Colleagues Tip Their Hats to Allen S. Lichter, MD, FASCO
After serving as ASCO’s CEO for 10 years, Allen S. Lichter, MD, FASCO, is stepping down. Dr. Lichter, who has been an ASCO member since 1980, has served the Society in numerous capacities. Along with his distinguished career at ASCO, Dr. Lichter is a nationally recognized radiation oncologist,...
2016 Oncology Meetings
MAY Lymphoma: State-of-the-Art in Biology Therapy, and Patient CareMay 13-14 • New York, New YorkFor more information: msklymphoma2016.com NCI “Sandpit” on Individual and Contextual Factors of Population-Level Cancer ControlMay 16-18 • Montgomery County, MarylandFor more...
Surgical Oncologist Suzanne L. Topalian, MD, Shines at the Forefront of Groundbreaking Research in Cancer Immunotherapy
Nationally recognized surgical oncologist and researcher Suzanne L. Topalian, MD, had an early interest in the arts as well as science and decided to major in English upon entering Wellesley College in Wellesley, Massachusetts. “I wanted to keep all my options open, so I also enrolled in a pre-med...
Noted Gastrointestinal Oncologist Leonard Saltz, MD, Tempers Optimism With Reality and Factors Cost Into the Equation of Value in Cancer Care
Leonard Saltz, MD, was born in New York, New York, and reared in Westchester County, in the suburbs of the City. Terrance Archer, his high-school biology teacher, whom Dr. Saltz described as a “force of nature,” a wonderful human being, and a major role model, influenced his nascent curiosity in...
In Memoriam
The ASCO Post remembers the following specialists in oncology who passed away in 2015–2016. Please write to editor@ASCOPost.com to recognize and pay tribute to others in a future issue. Mark R. Green, MD January 3, 1945–February 23, 2015 “Few people have impacted cancer clinical research in the...
Recipients of the David A. Karnofsky Memorial Award and Lecture
David A. Karnofsky, MD, dedicated himself to the pursuit of scientific excellence and the investigation of more effective therapies for cancer for nearly 30 years, from the time he was a resident at the Collis P. Huntington Memorial Hospital for Cancer Research of Harvard University, until his...
Physician-Researcher Carolyn Jean Presley, MD, Envisions Enhancing Geriatric Oncology
Carolyn Jean Presley, MD, a Robert Wood Johnson Foundation clinical scholar in medical oncology at the Yale Cancer Center, was born in Duluth, Minnesota, which hugs the north shore of Lake Superior, making it one of the nation’s coldest cities during its long winters. She grew up the middle child...
Lisa A. Newman, MD, MPH, FACS, FASCO, Balances Her Passions of Surgical Breast Oncology and Breast Cancer Disparity Research, Both Home and Abroad
Lisa A. Newman, MD, MPH, FACS, FASCO, Director of the Henry Ford Health System’s Breast Oncology Program, was born in New York, New York and, according to her, was blessed to have had parents who lived the African American version of the “American Dream.” Dr. Newman’s father was the son of...
A Pioneer in Lung Cancer Research, James L. Mulshine, MD, Champions Early Population-Based Lung Cancer Screening
A neighborhood doctor who told a good story was an unwitting mentor to internationally regarded lung cancer expert James L. Mulshine, MD. Born in Elizabeth, New Jersey, Dr. Mulshine relocated with his family to West Hartford, Connecticut, when he was a year old, and except for a brief hiatus on...
With a Strong Personal Connection to His Patients, Stephen P. Hunger, MD, Strives for a Cure for All Children With Leukemia
Nationally regarded children’s cancer specialist Stephen P. Hunger, MD, was born and reared in South Windsor, a small suburb of Hartford, Connecticut. Dr. Hunger grew up in the mid-1960s and 1970s, and in his words, “South Windsor was a pretty homogeneous experience. There wasn’t really any ethnic...
International Authority on Radiation Effects, Robert Peter Gale, MD, PhD, Has Pushed Scientific Boundaries in Search of Answers
It is widely reported that the first use of sargramostim (Leukine) in humans (granulocyte macrophage colony-stimulating factor; GM-CSF) was to treat victims of the Goiânia, Brazil, radiation accident in 1987. However, recently declassified documents show that sargramostim was first used a year...
About the Contributors
Ronald Piana is an independent writer and reporter with more than 20 years of experience in oncology communications and publishing. In addition to the profiles published in this special supplemental issue of The ASCO Post, Ron has written more than 100 news and feature articles, interviews, and...
Once a Vocational Nomad, Christine H. Chung, MD, Now Works to Promote Patient-Centered Care in Head and Neck Cancer
Christine H. Chung, MD, Chair of the Department of Head and Neck-Endocrine Oncology at Moffitt Cancer Center, Tampa, Florida, was born and reared in Seoul, Republic of Korea. Dr. Chung immigrated with her mother and two brothers to Los Angeles, where her family then resided. Dr. Chung did not speak ...
Celebrating ASCO 2016 Awards Recipients
Peter Paul Yu, MD, FACP, FASCO, Immediate Past President of ASCO and Chair of the Special Awards Selection Committee, announced the recipients of this year’s special awards. “The exceptional accomplishments of each of our awardees reflect their exemplary dedication to furthering cancer research and ...
With an Illustrious Career in Breast Oncology, Daniel F. Hayes, MD, FASCO, Follows in the Footsteps of Giants as ASCO President-Elect
ASCO President-Elect Daniel F. Hayes, MD, FASCO, was born in Shelbyville, Indiana, a small city in the center of the state. “My dream was to become a high school basketball and track and field coach; my older brother wanted to be a doctor, and his ambitions also began in first grade,” revealed Dr....
Allen S. Lichter, MD, FASCO, Reflects on His Career Path and His Tenure as ASCO CEO, and Predicts a Bright Future for Radiation Oncology
Choosing a career path is one of life’s most challenging decisions, but for Allen S. Lichter, MD, FASCO, deciding to become a doctor was inherently natural. He was born with a great mentor and role model: his father. “I was born and raised in Detroit. My father was a general practitioner in...
The Role of Occupational and Physical Therapy in Geriatric Oncology
With individuals aged 65 and older accounting for more than 50% of the U.S. population diagnosed with cancer,1 the demand for occupational and physical therapists to treat this population will increase in the years to come. Thus, it is essential for primary care providers to know that the...
A Perilous Time for Refugees With Cancer
The numbers are difficult to fathom. According to a report by the United Nations High Commissioner for Refugees (UNHCR), in 2015, over 60 million people worldwide were forcibly displaced as a result of conflict, persecution, generalized violence, or human rights violations.1 Over 9 million of those ...
Eribulin in Liposarcoma: A Closer Look at the Comparative Data
Sarcoma therapy is a challenge for oncologists. Soft-tissue sarcomas encompass more than 50 different histologies, resulting in limited familiarity of management for many treating physicians. In addition, there have been few available effective therapies. The phase III trial of eribulin (Halavan) ...
Eribulin Improves Overall Survival vs Dacarbazine in Previously Treated Advanced Liposarcoma or Leiomyosarcoma
In a phase III trial reported in The Lancet, Patrick Schöffski, MD, of University Hospitals Leuven, Leuven Cancer Institute, Belgium, and colleagues found that eribulin (Halaven) improved overall survival vs dacarbazine in patients with advanced or metastatic soft-tissue sarcoma who had received...
FDA Approves Lenvatinib in Combination With Everolimus in Advanced Renal Cell Carcinoma
On May 13, 2016, the U.S. Food and Drug Administration (FDA) approved lenvatinib capsules (Lenvima) in combination with everolimus (Afinitor) for the treatment of advanced renal cell carcinoma following one prior antiangiogenic therapy. Lenvatinib was first approved in 2015 for the treatment of...
Atezolizumab in Previously Treated Advanced Urothelial Carcinoma
The recent study by Rosenberg et al in The Lancet—summarized in this issue of The ASCO Post—is a very important paper in the field of bladder cancer therapy.1 It is the first phase II trial in metastatic transitional cell carcinoma that demonstrates the single-agent activity of the...
Anti–PD-L1 Antibody Atezolizumab Active in Previously Treated Advanced Urothelial Carcinoma
In a phase II trial reported in The Lancet, Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, and colleagues found that the anti–PD-L1 (programmed cell death ligand 1) antibody atezolizumab produced durable responses in a marked proportion of patients with previously treated...
Al B. Benson III, MD, Elected President of the National Patient Advocate Foundation Executive Board
Al B. Benson III, MD, Associate Director for Cooperative Groups at the Lurie Cancer Center, has been elected President of the National Patient Advocate Foundation’s (NPAF) Executive Board. An oncologist and Professor of Medicine in the Division of Hematology/Oncology at the Feinberg School of...
Curb Your Enthusiasm: No Benefit of Adjuvant Sorafenib or Sunitinib in Nonmetastatic Renal Cell Carcinoma
Renal cell carcinoma is the most common cancer of the kidneys. Up to 30% of patients present with advanced/metastatic disease, and recurrence can develop in patients at high risk treated by nephrectomy for localized tumors. Renal cell carcinoma is notoriously resistant to chemotherapy and...
No Disease-Free Survival Benefit of Adjuvant Sunitinib or Sorafenib in High-Risk Nonmetastatic Renal Cell Carcinoma
In the phase III ECOG-ACRIN E2805 trial reported in The Lancet by Naomi B. Haas, MD, of Abramson Cancer Center, University of Pennsylvania, and colleagues, no benefit of adjuvant vascular endothelial growth factor receptor (VEGFR) inhibitor treatment with sunitinib or sorafenib (Nexavar) was...
ASCO and European Association of Urology Agree on Bladder Cancer Guidelines
I like economies of scale, and thus it makes perfect sense that ASCO has set a formal process to allow potential endorsement of selected guidelines from other organizations, rather than redoing the whole process. Recently, we have seen the publication of a formal endorsement of the European...
ASCO Endorses European Association of Urology Guideline on Muscle-Invasive and Metastatic Bladder Cancers
As reported in the Journal of Clinical Oncology by Matthew I. Milowsky, MD, of the University of North Carolina Lineberger Comprehensive Cancer Center, and colleagues,1 ASCO has endorsed the European Association of Urology clinical practice guideline on muscle-invasive and metastatic bladder...
No Survival Benefit Reported With Chemoradiotherapy vs Continued Chemotherapy in Controlled Locally Advanced Pancreatic Cancer
In the phase III GERCOR LAP07 trial reported by Pascal Hammel, MD, of Beaujon Hospital, Clichy, France, and colleagues in JAMA, there was no survival benefit of chemoradiotherapy vs continued chemotherapy in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine...
ExteNET Trial of Neratinib: One Size Does Not Fit All in HER2-Positive Breast Cancer
Neratinib is an oral anti-HER2 tyrosine kinase inhibitor that has shown promising activity in the treatment of HER2-positive metastatic breast cancer.1 It differs from monoclonal antibodies such as trastuzumab (Herceptin) because, as a small molecule, neratinib blocks the ATP binding site on the...
